VERTEX PHARMACEUTICALS ($VRTX) posted quarterly earnings results on Monday, August 4th. The company reported earnings of $4.52 per share, beating estimates of $4.35 by $0.17. The company also reported revenue of $2,964,700,000, beating estimates of $2,963,508,530 by $1,191,470.
You can see Quiver Quantitative's $VRTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VERTEX PHARMACEUTICALS Insider Trading Activity
VERTEX PHARMACEUTICALS insiders have traded $VRTX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- DAVID ALTSHULER (EVP, Chief Scientific Officer) has made 0 purchases and 7 sales selling 12,976 shares for an estimated $6,420,269.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 4 sales selling 7,854 shares for an estimated $3,844,667.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 3 sales selling 6,164 shares for an estimated $2,912,812.
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 5,090 shares for an estimated $2,332,768.
- CHARLES F JR WAGNER (EVP & Chief Financial Officer) sold 3,298 shares for an estimated $1,649,000
- KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 2,931 shares for an estimated $1,363,231.
- SANGEETA N. BHATIA sold 400 shares for an estimated $202,344
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VERTEX PHARMACEUTICALS Hedge Fund Activity
We have seen 738 institutional investors add shares of VERTEX PHARMACEUTICALS stock to their portfolio, and 785 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS added 4,107,393 shares (+39.4%) to their portfolio in Q1 2025, for an estimated $1,991,346,274
- GAMMA INVESTING LLC removed 2,420,358 shares (-99.8%) from their portfolio in Q2 2025, for an estimated $1,077,543,381
- FMR LLC removed 1,491,862 shares (-16.2%) from their portfolio in Q1 2025, for an estimated $723,284,534
- JPMORGAN CHASE & CO added 1,442,538 shares (+22.8%) to their portfolio in Q1 2025, for an estimated $699,371,273
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,226,527 shares (+72.5%) to their portfolio in Q1 2025, for an estimated $594,644,820
- JENNISON ASSOCIATES LLC added 1,089,063 shares (+21.5%) to their portfolio in Q2 2025, for an estimated $484,850,847
- WELLINGTON MANAGEMENT GROUP LLP removed 461,336 shares (-7.8%) from their portfolio in Q1 2025, for an estimated $223,664,919
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VERTEX PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $VRTX stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 2 purchases worth up to $100,000 on 03/13, 02/24 and 1 sale worth up to $50,000 on 05/12.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/20.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
VERTEX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/23/2025
- JP Morgan issued a "Overweight" rating on 05/06/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/06/2025
- B of A Securities issued a "Buy" rating on 03/31/2025
- UBS issued a "Buy" rating on 02/11/2025
- Truist Securities issued a "Buy" rating on 02/11/2025
To track analyst ratings and price targets for VERTEX PHARMACEUTICALS, check out Quiver Quantitative's $VRTX forecast page.
VERTEX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 13 analysts offer price targets for $VRTX in the last 6 months, with a median target of $503.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $517.0 on 07/14/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $550.0 on 06/23/2025
- Matthew Harrison from Morgan Stanley set a target price of $460.0 on 06/20/2025
- Brian Abrahams from RBC Capital set a target price of $420.0 on 06/17/2025
- Greg Harrison from Scotiabank set a target price of $442.0 on 05/06/2025
- Carter Gould from Cantor Fitzgerald set a target price of $535.0 on 05/06/2025
- David Risinger from Leerink Partners set a target price of $503.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
